Indication
Treatment of patients with moderate to severe Alzheimer's disease.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Loading your page…
Loading your page…
Alzheimer Disease
Marketing Authorisation Holder: Merz Pharmaceuticals GmbH
EMA Authorisation: 17/05/2002
INN: memantine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Axura: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.